Sign In
Buy DYN
$25.18
-0.550 (-2.14%)
At Close: Jul 31, 2026
Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
04:30pm, Wednesday, 29'th Jul 2026
- Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD accepted for review by FDA; Priority Review granted; PDUFA target action date set for January 21, 2027 -
- Company's third program to enter clinical development leveraging FORCE platform with the goal of delivering functional improvement in rare neuromuscular disease -
Fifth Third Bancorp Buys New Shares in Dyne Therapeutics, Inc. $DYN
04:03am, Monday, 27'th Jul 2026
Fifth Third Bancorp purchased a new stake in Dyne Therapeutics, Inc. (NASDAQ: DYN) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fu
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 24'th Jul 2026
WALTHAM, Mass., July 24, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven
WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven
Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock
10:46pm, Tuesday, 21'st Jul 2026
WALTHAM, Mass. , July 21, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically drive
Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock
10:46pm, Tuesday, 21'st Jul 2026
WALTHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
04:46pm, Tuesday, 21'st Jul 2026
WALTHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven
DYN Stock Rises 19.2% in 3 Months: What's Driving the Rally?
11:20am, Tuesday, 21'st Jul 2026
Dyne gains momentum as FDA priority review for its lead DMD therapy and progress in its DM1 program strengthen confidence in its pipeline.
Dyne Therapeutics: A Buy, With Caveats, On DMD Progress
02:35pm, Monday, 20'th Jul 2026
Dyne Therapeutics receives FDA Priority Review for z-rostudirsen in DMD, with a potential U.S. launch in Q1 2027. DYN demonstrates best-in-class dystrophin expression in registrational trials, targeti
- Priority Review granted; PDUFA target action date set for January 21, 2027 - - Submission for Accelerated Approval based on dystrophin as a surrogate endpoint - - In the registrational expansion coh
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?
09:21am, Saturday, 04'th Jul 2026
Dyne Therapeutics is advancing a clinical-stage platform specifically targeting genetically driven neuromuscular diseases. Recursion Pharmaceuticals utilizes an artificial intelligence OS to accelerat
Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026?
11:38am, Wednesday, 01'st Jul 2026
Dyne Therapeutics focuses on high-potential therapies for rare neuromuscular diseases using its proprietary FORCE platform. Vertex Pharmaceuticals maintains a dominant market share in cystic fibrosis
Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
11:05am, Friday, 26'th Jun 2026
Dyne is advancing therapies for rare muscle diseases while Viking targets the booming weight-loss market. See how their financials and risk profiles compare.
Biotech ETF Index Surges 10% After Rebalance
11:31am, Thursday, 25'th Jun 2026
After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs ETF (SBIO) gained over 10% in just six trading days beginning June 18. Key Takeaways: SBIO's underly
